NEKTAR THERAPEUTICS Reports FY2023 Q2 Earnings with 5.0% Decrease in Revenue from Last Year

August 11, 2023

🌥️Earnings Overview

On August 8 2023, NEKTAR THERAPEUTICS ($NASDAQ:NKTR) released their FY2023 Q2 earnings results, showing a 5.0% decrease in total revenue from the same period last year, at USD 20.5 million. Net income increased significantly from the previous year’s -159.1 million to -51.1 million.


GoodWhale conducted an analysis of NEKTAR THERAPEUTICS‘s wellbeing, resulting in a Star Chart classification of ‘elephant’. This means that the company is rich in assets after deducting off liabilities. Such a company would be of interest to investors looking for long-term prospects with stability and potential for growth. Unfortunately, NEKTAR THERAPEUTICS has a low health score of 3/10 with regard to its cashflows and debt, meaning it is less likely to safely ride out any crisis without the risk of bankruptcy. However, it is strong in asset and profitability, and weak in dividend and growth. This may be of interest to investors looking for quick returns or those hoping for a long-term investment that will generate returns when the market recovers. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Nektar Therapeutics. More…

    Total Revenues Net Income Net Margin
    87.74 -306.88 -252.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Nektar Therapeutics. More…

    Operations Investing Financing
    -267.5 365.83 1.51
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Nektar Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    494.28 297.32 1.04
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Nektar Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -18.6% -316.0%
    FCF Margin ROE ROA
    -307.0% -79.2% -35.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company’s competitors include Bristol-Myers Squibb Co, Merck & Co Inc, Eli Lilly and Co.

    – Bristol-Myers Squibb Co ($NYSE:BMY)

    Bristol-Myers Squibb Co, a pharmaceutical company, has a market cap of 155.38B as of 2022. The company has a Return on Equity of 17.43%. Bristol-Myers Squibb Co is engaged in the discovery, development, manufacture, and sale of biopharmaceutical products.

    – Merck & Co Inc ($NYSE:MRK)

    Merck & Co Inc is a global health care company that offers a wide range of products and services to help people lead healthier lives. The company has a market cap of 247.53B as of 2022 and a return on equity of 28.84%. The company’s products and services include prescription and over-the-counter medications, vaccines, biologic therapies, and consumer care and animal health products. The company also provides services such as marketing, research, and development, and manufacturing. Merck & Co Inc’s mission is to help people around the world live healthier lives by providing them with the products and services they need.

    – Eli Lilly and Co ($NYSE:LLY)

    Eli Lilly and Co is a pharmaceutical company with a market cap of 333.81B as of 2022. Its return on equity is 45.88%. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly and Co manufactures and markets pharmaceutical products in the United States, Europe, and Canada. The company’s products include Zyprexa, Prozac, Cymbalta, and Cialis.


    Nektar Therapeutics has reported its second quarter earnings results for FY2023, revealing a 5.0% decrease in total revenue from the same period a year earlier. Despite this drop in revenue, the company saw an improvement in its net income, with a negative 51.1 million compared to the previous year’s negative 159.1 million. Investors should take into consideration Nektar’s long-term prospects when considering their investment, and consider whether the current dip in revenue could be reversed in upcoming quarters. With the right strategies and management, Nektar could become a lucrative investment in the future.

    Recent Posts

    Leave a Comment